Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 8/20 | 0.53 |
| ▸ | PARP1 | P09874 | 7/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.48 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7661541 | 0.84 | HDAC6 (0.48) | ACVR1PARP1CHEK1PIM1AKT1 | |
| SCHEMBL8622180 | 0.81 | ACVR1 (0.73) | ACVR1PARP1CHEK1PIM1AKT1 | |
| SCHEMBL6773423 | 0.77 | ACVR1 (0.33) | ACVR1 | |
| SCHEMBL6767763 | 0.77 | IP6K1 (0.45) | ACVR1PARP1CHEK1PIM1AKT1 | |
| SCHEMBL8782182 | 0.77 | ACVR1 (0.57) | ACVR1PARP1CHEK1PIM1AKT1 | |
| SCHEMBL7980737 | 0.75 | ACVR1 (0.67) | ACVR1PARP1CHEK1PIM1AKT1 | |
| SCHEMBL13820309 | 0.74 | PARP1 (0.78) | ACVR1PARP1CHEK1PIM1AKT1 | |
| SCHEMBL11384943 | 0.72 | PARG (0.45) | PARP1 | |
| SCHEMBL6869415 | 0.71 | ACVR1 (0.63) | ACVR1PARP1CHEK1PIM1AKT1 | |
| SCHEMBL8782197 | 0.71 | ACVR1 (0.63) | ACVR1PARP1CHEK1PIM1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | ACVR1 3357/4885PARP1 1602/4885CHEK1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.